Ketamine is not considered safe for routine use during pregnancy, though it has a limited role in specific medical situations under close supervision. The drug crosses the placenta within seconds and reaches the fetus at concentrations that can exceed the mother’s own blood levels. While brief, controlled exposure during cesarean delivery has not been linked to immediate harm in newborns, animal research raises serious concerns about the effects of longer or repeated exposure on the developing fetal brain.
How Quickly Ketamine Reaches the Fetus
Ketamine passes through the placenta faster than most drugs used in anesthesia. After an intravenous injection, ketamine levels in the baby’s umbilical cord blood surpass the mother’s blood levels in under two minutes. Peak fetal concentrations occur roughly 100 to 125 seconds after the injection. This rapid transfer means the fetus is exposed almost immediately, leaving very little margin between the mother receiving the drug and the baby feeling its effects.
This speed is one reason ketamine’s safety profile depends heavily on how much is given, how long the exposure lasts, and at what stage of pregnancy it occurs.
Brief Use During Cesarean Delivery
The clearest safety data comes from cesarean sections, where ketamine is sometimes used as an induction agent to put the mother under general anesthesia. In this context, the exposure is short, typically a single dose under 1 mg/kg of body weight. Studies comparing neonatal outcomes after ketamine induction found that newborns had normal Apgar scores (the standard measure of a baby’s condition at birth) and healthy blood oxygen levels, provided the time between induction and delivery was under 10 minutes. No increase in neonatal respiratory depression was observed in these cases.
This does not mean ketamine is risk-free during delivery. It means that a single, low, carefully timed dose appears to be tolerated by the newborn when used by an experienced anesthesia team in an operating room. The key factors are keeping the dose low and the delivery fast.
Effects on the Uterus
Ketamine’s impact on uterine muscle depends on the stage of pregnancy. In early pregnancy, ketamine causes the uterus to contract with a force comparable to ergometrine, a drug specifically used to induce uterine contractions. The average increase in uterine pressure was about 16 mm Hg. In late pregnancy, however, ketamine had essentially no effect on uterine tone, with a negligible change of roughly negative 1.3 mm Hg.
This distinction matters. In early pregnancy, ketamine-induced contractions could theoretically pose a risk. In late pregnancy or during cesarean delivery, the uterine effects are minimal. Ketamine also raises maternal blood pressure and heart rate, which in higher doses could reduce blood flow through the uterine arteries. At doses below 1 mg/kg, these cardiovascular changes are generally manageable.
Fetal Brain Development Concerns
The most troubling evidence comes from animal studies. Research conducted in rhesus macaques, primates whose brain development closely resembles human fetal development, found that ketamine exposure caused a dramatic increase in brain cell death. Fetal monkeys exposed to ketamine at a gestational stage equivalent to the late second trimester in humans showed a 4.9-fold increase in dying neurons compared to unexposed controls. That translates to roughly 890,000 more brain cells undergoing programmed death than would normally occur.
The mechanism involves a process called apoptosis, where brain cells essentially self-destruct. Ketamine blocks a receptor critical to neuron survival during early development. When that receptor is blocked for extended periods, developing neurons interpret the signal as a cue to die. In these studies, the damage was widespread across the brain rather than limited to one region.
These findings come with important caveats. The ketamine exposures in the primate studies lasted hours, far longer than the brief doses used during a cesarean section. A single, short exposure may not produce the same degree of damage. But repeated or prolonged use, such as recreational ketamine use or extended infusions, raises much greater concern. No one has been able to study this directly in human pregnancies for obvious ethical reasons, so the exact threshold of harm remains unknown.
Birth Defects and First Trimester Exposure
Whether ketamine causes structural birth defects in humans is still an open question. According to a MotherToBaby fact sheet published by the National Library of Medicine, there is not enough evidence to say definitively whether ketamine increases the baseline 3% risk of birth defects that exists in any pregnancy. Some studies suggest it can affect fetal brain development, but large-scale human data on physical malformations is lacking.
The absence of clear evidence here is not reassurance. It reflects a gap in the research rather than proof of safety. Most pregnant people are not exposed to ketamine in controlled research settings, so the available human data is limited to case reports and observational studies with small numbers.
Ketamine for Depression During Pregnancy
Low-dose ketamine and its close relative esketamine have gained attention as treatments for severe depression, including in the perinatal period. A single low dose (0.2 to 0.25 mg/kg infused over 40 minutes) has been studied for postpartum depression and appears to be tolerated in that narrow context. However, perinatal depression tends to be less severe than the treatment-resistant depression studied in most ketamine trials, which complicates direct comparisons.
Using ketamine infusions during pregnancy itself, rather than after delivery, is a different situation entirely because of the placental transfer and fetal brain concerns described above. There are currently no large clinical trials establishing the safety of repeated ketamine infusions for depression during pregnancy. For someone with treatment-resistant depression who is pregnant, the decision involves weighing the real risks of untreated severe depression (which carries its own dangers for both mother and baby) against the uncertain but potentially serious risks of fetal ketamine exposure.
Recreational Use Carries the Highest Risk
The safety concerns escalate significantly with recreational ketamine use during pregnancy. Street ketamine involves unknown doses, unknown purity, repeated exposures, and often longer durations of effect, all of which amplify every risk described above. The animal data on prolonged exposure and fetal brain cell death is most relevant to this pattern of use. Recreational doses are also more likely to raise blood pressure and heart rate to levels that reduce blood flow to the uterus, and the uterine contractions caused by ketamine in early pregnancy add another layer of risk.
If you’ve used ketamine before knowing you were pregnant, a single exposure is unlikely to have the same impact as repeated use, but it’s worth discussing with your prenatal care provider so they can monitor appropriately.